Clinical trials: CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
- Condition CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
T-ALL
CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia
Patients with acute leukemia derived from T lymphocytes have the characteristics of high expression of CD7 antigen, such as acute T lymphocyte leukemia (T-ALL).CAR-T therapy is to genetically modify the patient's T lymphocytes to…
- Trial name
- NCT04785833
- Testing
- T cell injection targeting CD7 chimeric antigen receptor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.